HANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000

Bulletin Express05-19

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a volume-weighted average cost of HKD 29.60 per share and a total cash outlay of approximately HKD 0.78 million.

Following the transaction, the number of shares held as treasury stock increased to 709,000, while the company’s issued share capital excluding treasury shares declined to 135.51 million. Total issued shares remained unchanged at 136.22 million, making the latest buyback equivalent to 0.02% of the outstanding shares prior to the repurchase.

The purchase forms part of the mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 709,000 shares, representing 0.52% of the authorised limit.

Under Hong Kong Exchange rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119726518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119726518","market":"us","top_or_hot":-1,"title":"HANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a volume-weighted average cost of HKD 29.60 per share and a total cash outlay of approximately HKD 0.78 million.</p>\n<p>Following the transaction, the number of shares held as treasury stock increased to 709,000, while the company’s issued share capital excluding treasury shares declined to 135.51 million. Total issued shares remained unchanged at 136.22 million, making the latest buyback equivalent to 0.02% of the outstanding shares prior to the repurchase.</p>\n<p>The purchase forms part of the mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 709,000 shares, representing 0.52% of the authorised limit.</p>\n<p>Under Hong Kong Exchange rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Buys Back 26,500 H-Shares; Treasury Stock Climbs to 709,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-19 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a volume-weighted average cost of HKD 29.60 per share and a total cash outlay of approximately HKD 0.78 million.</p>\n<p>Following the transaction, the number of shares held as treasury stock increased to 709,000, while the company’s issued share capital excluding treasury shares declined to 135.51 million. Total issued shares remained unchanged at 136.22 million, making the latest buyback equivalent to 0.02% of the outstanding shares prior to the repurchase.</p>\n<p>The purchase forms part of the mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 709,000 shares, representing 0.52% of the authorised limit.</p>\n<p>Under Hong Kong Exchange rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1119726518","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119726518","pubTimestamp":1779192263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克生物-B回购26,500股H股；库存股攀升至709,000股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market repurchase of 26,500 H-shares on 19 May 2026. The shares were bought at prices ranging from HKD 29.00 to HKD 30.50, translating into a volume-weighted average cost of HKD 29.60 per share and a total cash outlay of approximately HKD 0.78 million.\nFollowing the transaction, the number of shares held as treasury stock increased to 709,000, while the company’s issued share capital excluding treasury shares declined to 135.51 million. Total issued shares remained unchanged at 136.22 million, making the latest buyback equivalent to 0.02% of the outstanding shares prior to the repurchase.\nThe purchase forms part of the mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 709,000 shares, representing 0.52% of the authorised limit.\nUnder Hong Kong Exchange rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119726518","isCrawlerRequest":true}